1. Home
  2. KURA vs REAX Comparison

KURA vs REAX Comparison

Compare KURA & REAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KURA
  • REAX
  • Stock Information
  • Founded
  • KURA 2014
  • REAX 2018
  • Country
  • KURA United States
  • REAX United States
  • Employees
  • KURA N/A
  • REAX N/A
  • Industry
  • KURA Biotechnology: Biological Products (No Diagnostic Substances)
  • REAX
  • Sector
  • KURA Health Care
  • REAX
  • Exchange
  • KURA Nasdaq
  • REAX Nasdaq
  • Market Cap
  • KURA 1.3B
  • REAX 1.1B
  • IPO Year
  • KURA N/A
  • REAX N/A
  • Fundamental
  • Price
  • KURA $15.92
  • REAX $4.95
  • Analyst Decision
  • KURA Strong Buy
  • REAX Strong Buy
  • Analyst Count
  • KURA 7
  • REAX 2
  • Target Price
  • KURA $29.83
  • REAX $5.25
  • AVG Volume (30 Days)
  • KURA 821.5K
  • REAX 774.1K
  • Earning Date
  • KURA 11-07-2024
  • REAX 11-07-2024
  • Dividend Yield
  • KURA N/A
  • REAX N/A
  • EPS Growth
  • KURA N/A
  • REAX N/A
  • EPS
  • KURA N/A
  • REAX N/A
  • Revenue
  • KURA N/A
  • REAX $1,095,350,000.00
  • Revenue This Year
  • KURA N/A
  • REAX $77.75
  • Revenue Next Year
  • KURA N/A
  • REAX $27.76
  • P/E Ratio
  • KURA N/A
  • REAX N/A
  • Revenue Growth
  • KURA N/A
  • REAX 81.37
  • 52 Week Low
  • KURA $9.06
  • REAX $1.28
  • 52 Week High
  • KURA $24.17
  • REAX $6.75
  • Technical
  • Relative Strength Index (RSI)
  • KURA 34.68
  • REAX 40.26
  • Support Level
  • KURA $16.55
  • REAX $5.25
  • Resistance Level
  • KURA $19.73
  • REAX $6.61
  • Average True Range (ATR)
  • KURA 0.98
  • REAX 0.38
  • MACD
  • KURA -0.05
  • REAX -0.05
  • Stochastic Oscillator
  • KURA 8.86
  • REAX 1.19

About KURA Kura Oncology Inc.

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

About REAX The Real Brokerage Inc.

The Real Brokerage Inc is a technology-powered real estate brokerage firm. It has developed, integrated, and adopted various mobile and desktop-focused technologies to create a comprehensive offering to its agents and to assist Real with its brokerage operations. The group delivers a cloud-based platform to improve efficiencies and empower real estate agents to provide a seamless end-to-end experience for homebuyers and sellers. The company generates its maximum revenue from the United States.

Share on Social Networks: